CoLucid Pharmaceuticals Inc (CLCD) was Reiterated by Stifel to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 30 from a previous price target of $27 . Stifel advised their investors in a research report released on Sep 19, 2016.
Many Wall Street Analysts have commented on CoLucid Pharmaceuticals Inc. Company shares were Reiterated by Stifel on Sep 19, 2016 to “Buy”, Firm has raised the Price Target to $ 30 from a previous price target of $27 .
On the company’s financial health, CoLucid Pharmaceuticals Inc reported $-0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 10, 2015. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.97 EPS.
CoLucid Pharmaceuticals Inc opened for trading at $26.77 and hit $28.44 on the upside on Friday, eventually ending the session at $28.13, with a gain of 5.28% or 1.41 points. The heightened volatility saw the trading volume jump to 1,132,699 shares. Company has a market cap of $431 M.
In a different news, on Sep 16, 2016, Thomas P. Mathers (Chief Executive Officer) sold 6,000 shares at $23.54 per share price. According to the SEC, on Sep 7, 2016, Linda C. Hogan (Head, Bus. Dev. and Strategy) sold 48,736 shares at $19.75 per share price. On Aug 31, 2016, Raymond Skwierczynski (Head,Pharmaceutical Operations) sold 150 shares at $10.86 per share price, according to the Form-4 filing with the securities and exchange commission.
CoLucid Pharmaceuticals Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate Lasmiditan for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.